ETX-155 is a Small Molecule owned by Eliem Therapeutics, and is involved in 4 clinical trials, of which 2 were completed, and 2 are planned.
ETX-155 acts by agonizing GABA A-type receptor. It is a neuroactive steroid that binds at the neurosteroid site on extrasynaptic and synaptic receptors. Binding at the extrasynaptic and synaptic receptors causes enhanced GABAergic tone and GABAergic synaptic transmission, leading to decreased neuron excitability and firing.
The revenue for ETX-155 is expected to reach a total of $3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the ETX-155 NPV Report.
ETX-155 is originated and owned by Eliem Therapeutics.
ETX-155 Overview
ETX-155 is under development for the treatment of major depressive disorder (MDD), perimenopausal depression and focal onset seizures (FOS). The drug candidate is administered through oral route. It is a next-generation, neuroactive steroid new chemical entity (NCE) that acts by targeting GABA A type receptor.
Eliem Therapeutics Overview
Eliem Therapeutics is a biotechnology company that develops and markets novel therapies for the treatment of chronic pain, psychiatry, epilepsy and other peripheral and central nervous system disorders. The company is headquartered in Redmond, Washington, the US.
The operating loss of the company was US$35.7 million in FY2021, compared to an operating loss of US$20.9 million in FY2020. The net loss of the company was US$47.5 million in FY2021, compared to a net loss of US$20.7 million in FY2020.
Quick View – ETX-155
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Companies |
|
Highest Development Stage |
|